Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | BRD4 | O60885 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | HTR2C | P28335 | 2/20 | 0.51 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.51 |
| ▸ | ADRA1D | P25100 | 4/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18324797 | 0.88 | ADRA1D (0.60) | KDM4EBRD4ALDH1A1POLBCREBBP | |
| SCHEMBL18324713 | 0.84 | KDM4E (0.60) | CYP2D6KDM4EBRD4ALDH1A1POLB | |
| SCHEMBL18324801 | 0.83 | KDM4E (0.61) | CYP2D6KDM4EBRD4ALDH1A1POLB | |
| SCHEMBL18324679 | 0.82 | KDM4E (0.64) | KDM4EBRD4ALDH1A1POLBCREBBP | |
| SCHEMBL26912090 | 0.81 | CYP2D6 (0.65) | CYP2D6KDM4EBRD4ALDH1A1POLB | |
| SCHEMBL18324710 | 0.80 | KDM4E (0.57) | KDM4EBRD4ALDH1A1POLBCREBBP | |
| SCHEMBL18324895 | 0.80 | KDM4E (0.61) | KDM4EBRD4ALDH1A1POLBCREBBP | |
| SCHEMBL23153221 | 0.79 | KDM4E (0.56) | KDM4EBRD4ALDH1A1POLBCREBBP | |
| SCHEMBL18324711 | 0.79 | KDM4E (0.60) | KDM4EBRD4ALDH1A1POLBCREBBP | |
| SCHEMBL18324897 | 0.79 | KDM4E (0.60) | KDM4EBRD4ALDH1A1POLBCREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3082802-B1 | TRYPTOPHAN-2,3-DIOXYGENASE (TDO) AND/OR INDOLAMINE-2,3-DIOXYGENASE (IDO) INHIBITORS AND THEIR USE | IOMET PHARMA LTD (GB) | 2020-02-26 | — | — | EP | disclosed |
| US-9931347-B2 | Pharmaceutical compound | IOMET PHARMA LTD. (US) | 2018-04-03 | — | — | US | disclosed |
| US-9931347-B2 | Pharmaceutical compound | IOMET PHARMA LTD. (US) | 2018-04-03 | — | — | US | disclosed |
| US-20160367564-A1 | Pharmaceutical Compound | IOMET PHARMA LTD. (GB) | 2016-12-22 | — | — | US | disclosed |
| US-20160367564-A1 | Pharmaceutical Compound | IOMET PHARMA LTD. (GB) | 2016-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160367564-A1 | Pharmaceutical Compound | TDO2, IDO1, IDO2 | CYP2D6 17/4885KDM4E 465/4885BRD4 1542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.